» Articles » PMID: 30508377

Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using Cu-Labeled Macrin

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2018 Dec 4
PMID 30508377
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) are widely implicated in cancer progression, and TAM levels can influence drug responses, particularly to immunotherapy and nanomedicines. However, it has been difficult to quantify total TAM numbers and their dynamic spatiotemporal distribution in a non-invasive and translationally relevant manner. Here, we address this need by developing a pharmacokinetically optimized, Cu-labeled polyglucose nanoparticle (Macrin) for quantitative positron emission tomography (PET) imaging of macrophages in tumors. By combining PET with high-resolution in vivo confocal microscopy and ex vivo imaging of optically cleared tissue, we found that Macrin was taken up by macrophages with >90% selectivity. Uptake correlated with the content of macrophages in both healthy tissue and tumors ( R > 0.9) and showed striking heterogeneity in the TAM content of an orthotopic and immunocompetent mouse model of lung carcinoma. In a proof-of-principle application, we imaged Macrin to monitor the macrophage response to neo-adjuvant therapy, using a panel of chemotherapeutic and γ-irradiation regimens. Multiple treatments elicited 180-650% increase in TAMs. Imaging identified especially TAM-rich tumors thought to exhibit enhanced permeability and retention of nanotherapeutics. Indeed, these TAM-rich tumors accumulated >700% higher amounts of a model poly(d,l-lactic- co-glycolic acid)- b-polyethylene glycol (PLGA-PEG) therapeutic nanoparticle compared to TAM-deficient tumors, suggesting that imaging may guide patient selection into nanomedicine trials. In an orthotopic breast cancer model, chemoradiation enhanced TAM and Macrin accumulation in tumors, which corresponded to the improved delivery and efficacy of two model nanotherapies, PEGylated liposomal doxorubicin and a TAM-targeted nanoformulation of the toll-like receptor 7/8 agonist resiquimod (R848). Thus, Macrin imaging offers a selective and translational means to quantify TAMs and inform therapeutic decisions.

Citing Articles

Cyclodextrin Nanoparticles and Injectable Polymer-Nanoparticle Hydrogels for Macrophage-Targeted Delivery of Small-Molecule Drugs.

Soni S, Rodell C Methods Mol Biol. 2025; 2902:117-131.

PMID: 40029599 DOI: 10.1007/978-1-0716-4402-7_7.


Noninvasive in vivo imaging of macrophages: understanding tumor microenvironments and delivery of therapeutics.

Gangadaran P, Onkar A, Rajendran R, Goenka A, Oh J, Khan F Biomark Res. 2025; 13(1):20.

PMID: 39865337 PMC: 11770947. DOI: 10.1186/s40364-025-00735-9.


Scission-Enhanced Molecular Imaging (SEMI).

Quintana J, Carlson J, Scott E, Ng T, Miller M, Weissleder R Bioconjug Chem. 2024; .

PMID: 39255972 PMC: 11488501. DOI: 10.1021/acs.bioconjchem.4c00337.


A non-lipid nucleic acid delivery vector with dendritic cell tropism and stimulation.

Kim H, Halabi E, Enbergs N, Kohler R, Fei F, Garris C Theranostics. 2024; 14(7):2934-2945.

PMID: 38773971 PMC: 11103498. DOI: 10.7150/thno.95267.


Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype.

Sarkar B, Arlauckas S, Cuccarese M, Garris C, Weissleder R, Rodell C Front Immunol. 2024; 15:1331480.

PMID: 38545103 PMC: 10965546. DOI: 10.3389/fimmu.2024.1331480.


References
1.
Miller M, Chandra R, Cuccarese M, Pfirschke C, Engblom C, Stapleton S . Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med. 2017; 9(392). PMC: 6681815. DOI: 10.1126/scitranslmed.aal0225. View

2.
Nywening T, Wang-Gillam A, Sanford D, Belt B, Panni R, Cusworth B . Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016; 17(5):651-62. PMC: 5407285. DOI: 10.1016/S1470-2045(16)00078-4. View

3.
Liu R, Cao S, Hua Y, Keep R, Huang Y, Xi G . CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage. Stroke. 2017; 48(5):1369-1375. PMC: 5404936. DOI: 10.1161/STROKEAHA.117.016850. View

4.
Mohan J, Kohler R, Hill J, Weissleder R, Mathis D, Benoist C . Imaging the emergence and natural progression of spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A. 2017; 114(37):E7776-E7785. PMC: 5604023. DOI: 10.1073/pnas.1707381114. View

5.
Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View